Has Rashid Sharaf, MD received payments from drug or device companies?

Yes. Drug and device makers reported $340,321 in general payments to Rashid Sharaf, MD across 456 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Rashid Sharaf, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Rashid Sharaf, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Rashid Sharaf, MD

Nephrology · San Antonio, TXNPI 1265471155

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $271,850 of the $340,321 with a category attached, or 79.9%. Medtronic accounts for 73.4% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2024 at $88,377 and has fallen 75.5% since, to $21,634 in 2025. Among nephrology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$340,321in general payments, 2019–2025

Across 456 payments — averaging $746.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$250K
Lilly USA, LLC$40K
Boehringer Ingelheim$32K
Avenu Medical Inc.$10K
Covidien LP$7K
Venturemed Group, Inc.$285
plus $1K from 12 others

$320,507in research payments, 2019–2025

Across 17 payments — averaging $18,853 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Medtronic$321K

What the payments were for

Consulting fees$30,0509%
Speaking & faculty fees$271,85080%
Travel & lodging$23,4237%
Food & beverage$14,9984%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	324	$249,815
Lilly USA, LLC	38	$39,972
Boehringer Ingelheim	46	$31,607
Avenu Medical Inc.	4	$10,263
Covidien LP	11	$7,283
Venturemed Group, Inc.	3	$285
OPKO Pharmaceuticals, LLC	2	$270
Novartis	9	$168
GSK	4	$165
Calliditas Therapeutics US Inc.	1	$125
Bard Peripheral Vascular, Inc.	4	$112
Celonova Biosciences, Inc.	1	$81
Mozarc Medical US LLC	3	$74
Philips North America LLC	2	$33
Boston Scientific	1	$19
Nxstage Medical, Inc.	1	$19
Cormedix Inc.	1	$18
Biotronik Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$340,321 in reported general payments places this provider in the 95th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas →

Medicare billing

Part B allowed, 2024

$316,612

Medicare patients

496

Services billed

3,138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav	29	$191
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim	45	$181
ClopidogrelClopidogrel Bisulfate	47	$158
ConstuloseLactulose	44	$153
Lactulose	45	$150
Prednisone	66	$117
Gabapentin	12	$58
Cephalexin	11	$49
EnuloseLactulose	14	$47
Levofloxacin	21	$43

Paid to pharmacies, not to this prescriber.

Other nephrology in San Antonio

Luis VelezSan Antonio$505K
Carl DukesSan Antonio$238K
Pablo PergolaSan Antonio$164K
Varshasb BroumandSan Antonio$118K
Shweta BansalSan Antonio$89K
Rajeev NarayanSan Antonio$57K
Anwar GergesSan Antonio$50K
Matthew SchaeferSan Antonio$46K
Kumar SharmaSan Antonio$45K
Gerardo ChicaSan Antonio$39K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →